AR101367A1 - Pirimidinonas como inhibidores del factor xia - Google Patents

Pirimidinonas como inhibidores del factor xia

Info

Publication number
AR101367A1
AR101367A1 ARP150102426A ARP150102426A AR101367A1 AR 101367 A1 AR101367 A1 AR 101367A1 AR P150102426 A ARP150102426 A AR P150102426A AR P150102426 A ARP150102426 A AR P150102426A AR 101367 A1 AR101367 A1 AR 101367A1
Authority
AR
Argentina
Prior art keywords
independently selected
pyrimidinones
inhibitors
formula
xia factor
Prior art date
Application number
ARP150102426A
Other languages
English (en)
Inventor
m smith ii Leon
J Orwat Michael
J P Pinto Donald
R Wexler Ruth
Zhu Yeheng
R Ewing William
Balashanmuga Pabbisetty Kumar
Wang Yufeng
Yang Wu
Fang Tianan
De Lucca Indawati
R Corte James
K Dilger Andrew
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR101367A1 publication Critical patent/AR101367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o un estereoisómero, un tautómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde: el anillo A se selecciona independientemente de los restos de fórmula (2) y (3); el anillo B se selecciona independientemente de los restos de fórmula (4) y (5); R¹ se selecciona independientemente de H y C₁₋₄ alquilo; R² se selecciona independientemente de H, F, Cl, CF₃, CHF₂ y COOH; R³ se selecciona independientemente de H, CHF₂, CD₃, CH₃ y un resto de fórmula (6); R⁴ se selecciona independientemente de H y F; y R⁵ se selecciona independientemente de H, F, Cl, CH₃ y OCH₃.
ARP150102426A 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia AR101367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
AR101367A1 true AR101367A1 (es) 2016-12-14

Family

ID=53784023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102426A AR101367A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia

Country Status (34)

Country Link
EP (4) EP3089979B1 (es)
JP (4) JP6462865B2 (es)
KR (2) KR102269999B1 (es)
CN (3) CN114957255A (es)
AR (1) AR101367A1 (es)
AU (3) AU2015324530B2 (es)
CA (1) CA2963395C (es)
CL (1) CL2017000712A1 (es)
CO (1) CO2017003833A2 (es)
CY (2) CY1119678T1 (es)
DK (2) DK3293186T3 (es)
EA (1) EA031590B1 (es)
ES (3) ES2836270T3 (es)
HR (2) HRP20171950T1 (es)
HU (2) HUE052812T2 (es)
IL (2) IL251434B (es)
LT (2) LT3089979T (es)
MA (1) MA40123A1 (es)
MX (2) MX2017003695A (es)
MY (1) MY183987A (es)
NO (1) NO2721243T3 (es)
NZ (2) NZ731416A (es)
PE (2) PE20210922A1 (es)
PH (2) PH12017500580A1 (es)
PL (1) PL3089979T3 (es)
PT (2) PT3089979T (es)
RS (2) RS56786B1 (es)
SG (2) SG11201702576QA (es)
SI (2) SI3089979T1 (es)
TN (2) TN2017000112A1 (es)
TW (2) TWI769442B (es)
UY (1) UY36244A (es)
WO (1) WO2016053455A1 (es)
ZA (1) ZA201702478B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9777001B2 (en) * 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
NO2760821T3 (es) 2014-01-31 2018-03-10
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
CN107001391B (zh) 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
US10287288B2 (en) 2015-07-29 2019-05-14 Bristol-Myers Squibb Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties
CN107922393A (zh) 2015-07-29 2018-04-17 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200604A1 (es) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA202192753A1 (ru) * 2019-04-11 2022-01-11 Бристол-Маерс Сквибб Компани Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
US20220144836A1 (en) * 2019-04-11 2022-05-12 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
US20220204508A1 (en) 2019-04-16 2022-06-30 Medshine Discovery Inc. Macrocyclic derivatives acting as xia factor inhibitor
US20220281868A1 (en) 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
PE20231071A1 (es) * 2020-04-10 2023-07-17 Bristol Myers Squibb Co Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1- il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15- tetraazatriciclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－***－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
CN115215867B (zh) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
PL204653B1 (pl) 2001-09-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
ES2674745T3 (es) * 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
US9327839B2 (en) 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
SG11201403402VA (en) * 2011-12-21 2015-01-29 Ono Pharmaceutical Co Compounds
KR20150038369A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
KR20150038372A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
US9777001B2 (en) * 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
NO2760821T3 (es) * 2014-01-31 2018-03-10
NO2721243T3 (es) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
CN106795161A (zh) 2017-05-31
UY36244A (es) 2016-01-29
CA2963395C (en) 2023-03-14
TW202043228A (zh) 2020-12-01
AU2021245098A1 (en) 2021-10-28
PH12017500580B1 (en) 2017-08-30
SI3293186T1 (sl) 2021-01-29
WO2016053455A1 (en) 2016-04-07
TW201613923A (en) 2016-04-16
EP3828186A3 (en) 2021-07-28
RS61183B1 (sr) 2021-01-29
NZ731416A (en) 2024-01-26
EP3828186B1 (en) 2023-08-23
IL251434A0 (en) 2017-05-29
IL251434B (en) 2020-08-31
PT3089979T (pt) 2018-01-16
TW202310844A (zh) 2023-03-16
LT3089979T (lt) 2017-12-27
DK3089979T3 (en) 2018-01-15
JP2017530157A (ja) 2017-10-12
MA40123A1 (fr) 2017-09-29
PE20210922A1 (es) 2021-05-19
JP6462865B2 (ja) 2019-01-30
TWI692478B (zh) 2020-05-01
CY1119678T1 (el) 2018-04-04
AU2015324530B2 (en) 2019-10-24
MY183987A (en) 2021-03-17
SG11201702576QA (en) 2017-04-27
ES2655884T3 (es) 2018-02-22
IL276470A (en) 2020-09-30
PT3293186T (pt) 2020-12-09
AU2020200376B2 (en) 2021-07-08
NZ766570A (en) 2024-01-26
AU2021245098B2 (en) 2023-11-23
CA2963395A1 (en) 2016-04-07
PH12020500195A1 (en) 2021-02-08
EA201790595A1 (ru) 2017-07-31
JP2023134734A (ja) 2023-09-27
DK3293186T3 (da) 2020-12-14
TWI769442B (zh) 2022-07-01
CN110734435A (zh) 2020-01-31
SG10201911652TA (en) 2020-02-27
RS56786B1 (sr) 2018-04-30
LT3293186T (lt) 2020-12-28
MX2020010840A (es) 2020-11-06
PL3089979T3 (pl) 2018-02-28
JP6937734B2 (ja) 2021-09-22
EP3293186A1 (en) 2018-03-14
JP2021185182A (ja) 2021-12-09
KR20170057431A (ko) 2017-05-24
KR102269999B1 (ko) 2021-06-25
CL2017000712A1 (es) 2017-11-03
JP2019069989A (ja) 2019-05-09
EP4286372A3 (en) 2024-02-21
PE20170939A1 (es) 2017-07-13
ES2963267T3 (es) 2024-03-26
HRP20201927T1 (hr) 2021-02-05
KR20180126612A (ko) 2018-11-27
HUE052812T2 (hu) 2021-05-28
TN2018000229A1 (en) 2019-10-04
CN110734435B (zh) 2022-06-07
JP7317905B2 (ja) 2023-07-31
ZA201702478B (en) 2019-06-26
CY1123663T1 (el) 2022-03-24
EP3828186A2 (en) 2021-06-02
BR112017006702A2 (pt) 2017-12-26
TN2017000112A1 (en) 2018-07-04
EP3089979A1 (en) 2016-11-09
HRP20171950T1 (hr) 2018-02-23
PH12017500580A1 (en) 2017-08-30
ES2836270T3 (es) 2021-06-24
HUE038061T2 (hu) 2018-09-28
MX2017003695A (es) 2017-05-30
EP4286372A2 (en) 2023-12-06
EP3293186B1 (en) 2020-09-23
SI3089979T1 (sl) 2017-12-29
EA031590B1 (ru) 2019-01-31
IL276470B (en) 2021-04-29
CO2017003833A2 (es) 2017-07-11
NO2721243T3 (es) 2018-10-20
KR101921436B1 (ko) 2018-11-22
AU2015324530A1 (en) 2017-05-18
EP3089979B1 (en) 2017-10-18
AU2020200376A1 (en) 2020-02-06
CN114957255A (zh) 2022-08-30
CN106795161B (zh) 2019-10-15

Similar Documents

Publication Publication Date Title
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
AR099400A1 (es) Compuesto heterocíclico fusionado
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR102977A1 (es) Inhibidores de erk
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
EA201791684A1 (ru) Селективные ингибиторы bace1
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097866A1 (es) Derivados de 4-azaindol
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR111806A1 (es) Derivados de indol n-sustituidos
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
AR100439A1 (es) Derivados de carboxamida
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR106875A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза